Literature DB >> 26509654

ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway.

Natalia Brenda Fernández1, Daniela Lorenzo1, María Elisa Picco1, Gastón Barbero2, Leonardo Sebastián Dergan-Dylon1, María Paula Marks1, Hernán García-Rivello3, Liliana Gimenez4, Vivian Labovsky1, Luca Grumolato5, Pablo Lopez-Bergami6,7.   

Abstract

The Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) is primarily expressed by neural crest cells during embryogenesis. Following a complete downregulation after birth, ROR1 was shown to re-express in various types of cancers. Little is known about ROR1 expression and function in melanoma. Here we show that ROR1 is aberrantly expressed in both melanoma cell lines and tumors and that its expression associates with poor Post-Recurrence Survival of melanoma. Using gain- and loss-of-function approaches we found that ROR1 enhances both anchorage-dependent and -independent growth of melanoma cells. In addition, ROR1 decreases cell adhesion and increases cell motility and migration. Mechanistically, ROR1 was found to induce upregulation of Akt and the mesenquimal markers N-cadherin and vimentin. The regulation of N-cadherin by ROR1 relies on both Akt dependent and independent mechanisms. ROR1 does not affect Wnt canonical pathway but was found to be engaged in a positive feedback loop with Wnt5a. In summary, we show that ROR1 contributes to melanoma progression and is a candidate biomarker of poor prognosis. Although further studies are needed to confirm this possibility, the present work indicates that ROR1 is a good prospective target for melanoma cancer therapy.
© 2015 Wiley Periodicals, Inc. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Akt; N-cadherin; ROR1; melanoma; migration

Mesh:

Substances:

Year:  2015        PMID: 26509654     DOI: 10.1002/mc.22426

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  18 in total

1.  High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Authors:  Bing Cui; Emanuela M Ghia; Liguang Chen; Laura Z Rassenti; Christopher DeBoever; George F Widhopf; Jian Yu; Donna S Neuberg; William G Wierda; Kanti R Rai; Neil E Kay; Jennifer R Brown; Jeffrey A Jones; John G Gribben; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2016-11-04       Impact factor: 22.113

Review 2.  The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment.

Authors:  Pablo Lopez-Bergami; Gastón Barbero
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 3.  Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Authors:  Pavlína Janovská; Vítězslav Bryja
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

4.  ROR2 promotes epithelial-mesenchymal transition by hyperactivating ERK in melanoma.

Authors:  María Victoria Castro; Gastón Alexis Barbero; Paula Máscolo; María Belén Villanueva; Jérémie Nsengimana; Julia Newton-Bishop; Edith Illescas; María Josefina Quezada; Pablo Lopez-Bergami
Journal:  J Cell Commun Signal       Date:  2022-06-20       Impact factor: 5.782

5.  RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.

Authors:  Tomasz Radaszkiewicz; Michaela Nosková; Kristína Gömöryová; Olga Vondálová Blanářová; Katarzyna Anna Radaszkiewicz; Markéta Picková; Ráchel Víchová; Tomáš Gybeľ; Karol Kaiser; Lucia Demková; Lucia Kučerová; Tomáš Bárta; David Potěšil; Zbyněk Zdráhal; Karel Souček; Vítězslav Bryja
Journal:  Elife       Date:  2021-10-27       Impact factor: 8.140

6.  An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.

Authors:  Satyen Harish Gohil; Solange Rosa Paredes-Moscosso; Micaela Harrasser; Marzia Vezzalini; Aldo Scarpa; Emma Morris; Andrew M Davidoff; Claudio Sorio; Amit Chunilal Nathwani; Marco Della Peruta
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

7.  ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer.

Authors:  Jian-Kang Zhou; Yu-Zhu Zheng; Xue-Sha Liu; Qiheng Gou; Rui Ma; Cheng-Lin Guo; Carlo M Croce; Lunxu Liu; Yong Peng
Journal:  Oncotarget       Date:  2017-05-16

8.  Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.

Authors:  C E Henry; C Emmanuel; N Lambie; C Loo; B Kan; C J Kennedy; A de Fazio; N F Hacker; C E Ford
Journal:  Transl Oncol       Date:  2017-03-23       Impact factor: 4.243

9.  CTBP1 and metabolic syndrome induce an mRNA and miRNA expression profile critical for breast cancer progression and metastasis.

Authors:  Paula L Farré; Georgina D Scalise; Rocío B Duca; Guillermo N Dalton; Cintia Massillo; Juliana Porretti; Karen Graña; Kevin Gardner; Paola De Luca; Adriana De Siervi
Journal:  Oncotarget       Date:  2018-02-13

10.  Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion.

Authors:  Wei Geng; Wei Liang; Yanan Fan; Zhibin Ye; Lixiao Zhang
Journal:  Mol Med Rep       Date:  2017-10-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.